IL13RA2 and central nervous system cancer: Our next step of the research is to generate a murine counter part of CAR‐T cells with murine scFv‐IL‐13Rα2 as a transgene and test its quality attributes in vitro and in vivo in syngeneic mouse models using murine IL‐13Rα2 positive glioma cell lines such as GL121 and CTA2.